Volume 17 – Subject index

A
Antibody
– monoclonal 7, 62, 165, 173
Antigen
– butanol extraction 95
– cell surface 95
– human prostate-restricted 7
– membrane 147
– tumour 165, 173
– tumour specific 135
Anti-tumour
– activity 33
– resistance 90

B
BCG 18
BKV-transformed cells 28
Bladder carcinoma 165, 173
Breast-cancer patient 1
Breast-carcinoma xenograft 62

C
Chlorella vulgaris 90
Cimetidine 33, 69
Corynebacterium parvum 38
Cytotoxicity 117
– natural 100, 106, 130
– T cell 195
– T lymphocytes 205

D
Diphenhydramine 33

E
Endotoxin 33

G
Gallium 67 labelled antibody 62
Gammopathies
– monoclonal 112
Gynaecological malignancies 142

H
Head and neck cancer 160
Histamine receptor blockade 33
Hypersensitivity
– delayed 142
– natural delayed 76

I
Immune complexes 180
Immune function 218
Immune modulators 42
Immunity
– cell mediated 28
– tumour 73
Immunodeficiency syndrome 130
Immunodepression
– drug induced 213
Immunoscintigraphy 62
Immunosuppressive factors 200
Immunotherapy 18, 38, 124
Interferon 1, 69

L
Leukeamia
– acute myeloid 69
Levamisole 195
Liposome 135
Listeria monocytogenes 38
Lymph node 1
Lymphocyte 73, 76, 117
– cytotoxic T 205
– metastasis 100, 106
– proliferation 83
– Tγ 160

M
Macrophages 38, 190
Melanoma 95
Metastasis
– lymphocyte 100, 106
– murine 42
Meth A sarcoma 90
Monocyte 76
Muramyl dipeptide 154

N
Natural cytotoxicity 100, 106, 130
NK activity 1
NK cells 51, 73, 124

O
OK432
Ovarian cancer 124, 180, 190

P
Progestin 218
Polyoma virus 147

T
Thymic factor 51
Tumour
– antigen 165, 173
– autologous fresh human 83
– immunity 73, 124
– necrosis 154
– nonimmunogenic 117
– rejection 56
– specific antigens 135

V
Vaccine
– production 18
– standardization 18

X
Xenogenization 213